Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
CEO Steve Silvestro emphasized that OPRX is being increasingly viewed as a strategic commercialization partner, especially as pharma spending gets more focused and selective. Their platform's ROI — claimed at over 10:1 — and a 25% script lift in six months underscore its value proposition in a tightening market.
Also, more than 80% of its 2025 revenues are already contracted, and the company has begun shifting toward a subscription-based model, with early traction in data-as-a-service offerings. This could bring margin stability and predictability, which are key for long-term value creation. Though gross margin dipped slightly due to a higher mix of managed services, the company is confident about its ability sustain margins in the 60% range while expanding high-margin data solutions.
OptimizeRx also addressed concerns about regulatory pressures and pharma budget volatility, stating it hasn't seen meaningful headwinds yet. Rather, there's greater client focus on cost-effective digital solutions, which could be a tailwind for OPRX.
In a fiercely competitive digital health space where giants like Veeva are evolving rapidly, OPRX's integration of scalable omnichannel tools and data-driven insights may provide it with a durable edge if it continues to execute with discipline and agility. The challenge lies in scaling subscriptions while maintaining innovation to avoid margin pressures and defend its niche in a shifting digital engagement landscape.
Tools From Peers
Omnicell OMCL is reinforcing its digital health strategy through the Intelligence-Enabled Pharmacy vision. The company is scaling its OmniSphere platform — a cloud-based, AI-powered solution that offers predictive analytics and real-time medication inventory management. Despite near-term macroeconomic challenges and a pause in large-scale capex projects, Omnicell remains committed to automating and digitally transforming medication management workflows across hospitals and health systems.
OMCL's Advanced Services suite further integrates automation, analytics, and remote pharmacy services, aimed at optimizing clinical and financial outcomes for healthcare providers. These innovations position Omnicell as a strategic enabler of smart, data-driven pharmacy operations.
Teladoc Health TDOC is doubling down on digital mental health with its BetterHelp platform and recent acquisition of UpLift, an in-network virtual mental health provider. This move enables Teladoc to offer covered-benefits therapy options to users, improving conversion rates and reducing out-of-pocket costs. UpLift's network of more than 1,500 licensed professionals complements BetterHelp's reach of 35,000 therapists, supporting therapy, psychiatry and medication management.
Teladoc is also investing in AI-enabled clinical documentation tools and its Prism care delivery platform, which enhances integration across the virtual care ecosystem. These steps underline its ambition to deliver scalable, tech-driven behavioral and chronic care solutions globally.
OPRX's Price Performance, Valuation and Estimates
Shares of OptimizeRx have surged 187.9% year to date compared with the industry's growth of 18%.
Image Source: Zacks Investment Research
OPRX's forward 12-month P/S of 2.33X is lower than the industry's average of 8.86X, and also lower than its five-year median of 3.57X. However, it carries a Value Scoreof F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from the 2024 level.
Image Source: Zacks Investment Research
OptimizeRx stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Omnicell, Inc. (OMCL) : Free Stock Analysis Report
OptimizeRx Corp. (OPRX) : Free Stock Analysis Report
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
4 days ago
- CNBC
Wellness apps are popular and can be helpful, expert says, but they ‘don't have to prove they keep your data private': How to keep your info safe
There are many direct-to-consumer wellness apps out there: Meditation apps that guide you through mindfulness exercises and breath work or access to therapy right from your phone. Millions of people use apps like these every single day. And their growing popularity could point to a generally positive user experience. But experts warn of a few problematic aspects of these platforms. For one, many aren't regulated. "They don't have to prove that they work, they don't have to prove that they're safe," Vaile Wright, a psychologist and senior director at the American Psychological Association said on an episode of podcast "Speaking of Psychology." Another problem with these apps, she said, is that they "don't have to prove that they keep your data private." For example, "you might not want your boss to know that you're using an app to help you reduce your alcohol use," she said. If these tools aren't FDA cleared, they're not compliant with the Health Insurance Portability and Accountability Act, which protects sensitive health information. "There is no regulatory body or law that keeps your personal health information safe," Wright said. That means they can't guarantee that a data breach won't happen. This, of course, is not specific to wellness apps. These apps are also operating under a very specific business model that prioritizes their bottom line, she said. "But it's a challenging space to [prioritize profit] and so sometimes what happens with that tension is they make bad choices. In 2023, the federal trade commission issued a proposed order banning online therapy platform BetterHelp from sharing consumers' data for advertising. The company was charged with sharing sensitive customer data with Facebook and Snapchat. BetterHelp was required to pay consumers $7.8 million, which it began sending out in 2024. "It's not that these apps can't be helpful," Wright said. "I think they really can be. It's just consumers need to be aware of what are the benefits and what are the potential risks by using them." Before deciding to use one of these apps, read the terms of service and privacy policy. It's hard, Wright said, because you have to "get through it with all of the legalize." But it will at least keep you somewhat informed of their practices. You can also do your homework about the company at large. "You have to go to the website and really look at who's developing it," Wright said. "Do they have experts on there? Advisory boards? What are they saying that the app is built on? Is it built on some known psychological principle like cognitive behavioral therapy?" That kind of info can give you a sense of the company's internal policies. Ultimately, "you have to make your own informed decision about what you're comfortable with," she said. "It's about entering into it as informed as you can be."
Business Insider
4 days ago
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX) and Relay Therapeutics (RLAY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX – Research Report) and Relay Therapeutics (RLAY – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. OptimizeRx (OPRX) In a report released yesterday, Richard Baldry from Roth MKM reiterated a Buy rating on OptimizeRx, with a price target of $27.00. The company's shares closed last Thursday at $12.84, close to its 52-week high of $14.13. According to Baldry is a 5-star analyst with an average return of 17.4% and a 58.6% success rate. Baldry covers the Technology sector, focusing on stocks such as Zeta Global Holdings Corp, FiscalNote Holdings, and Research Solutions. Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $17.80, representing a 39.7% upside. In a report issued on August 4, Lake Street also maintained a Buy rating on the stock with a $19.00 price target. Relay Therapeutics (RLAY) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Relay Therapeutics yesterday. The company's shares closed last Thursday at $3.49, close to its 52-week low of $2.69. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 31.9% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.20, which is a 240.8% upside from current levels. In a report issued on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.50 price target.
Yahoo
6 days ago
- Yahoo
Evolent Health (EVH) Q2 Earnings Report Preview: What To Look For
Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting results this Thursday after the bell. Here's what investors should know. Evolent Health beat analysts' revenue expectations by 4.9% last quarter, reporting revenues of $483.6 million, down 24.4% year on year. It was a mixed quarter for the company, with full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Evolent Health's revenue to decline 29% year on year to $459.5 million, a reversal from the 37.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.08 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street's revenue estimates twice over the last two years. Looking at Evolent Health's peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 5%, beating analysts' expectations by 4.9%, and Hims & Hers Health reported revenues up 72.6%, falling short of estimates by 1.1%. Omnicell's stock price was unchanged after the resultswhile Hims & Hers Health was down 12.5%. Read our full analysis of Omnicell's results here and Hims & Hers Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Evolent Health is down 18.4% during the same time and is heading into earnings with an average analyst price target of $15.31 (compared to the current share price of $9.50). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
